Research Papers:
Baicalein has protective effects on the 17β-estradiol-induced transformation of breast epithelial cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2196 views | HTML 2853 views | ?
Abstract
Yan Chen1,2,*, Jing Wang1,*, Duan-Yang Hong1, Lin Chen1, Yan-Yan Zhang1, Yi-Ni Xu1, Di Pan1,2, Ling-Yun Fu1,2, Ling Tao1, Hong Luo1, Xiang-Chun Shen1,2
1The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability, Guizhou Medical University, Huaxi university town, Guian new district 550025, Guizhou, People’s Republic of China
2Department of Pharmacology of Chinese Material Medica, Guizhou Medical University, Huaxi university town, Guian new district 550025, Guizhou, People’s Republic of China
*These authors have contributed equally to this work
Correspondence to:
Xiang-Chun Shen, email: [email protected]
Keywords: baicalein, breast cancer, chemoprevention, 17β-estradiol, estrogen receptor
Received: August 24, 2016 Accepted: December 13, 2016 Published: January 02, 2017
ABSTRACT
Epidemiologic and systematic studies have indicated that flavonoid consumption is associated with a lower incidence of breast cancer. Baicalein is the primary flavonoid derived from the roots of Scutellaria baicalensis Georgi. In the current study, the long-term exposure of breast epithelial cells to 17β-estradiol (E2) was used to investigate the chemopreventive potential of baicalein on neoplastic transformation. The results demonstrated that baicalein significantly inhibited E2-induced cell growth, motility, and invasiveness, and suppressed E2-induced misshapen acini formation in 3D cultures. Furthermore, it inhibited the ability of E2-induced cells to form clones in agarose and tumors in NOD/SCID immunodeficient mice. Docking studies using Sybyl-X 1.2 software showed that baicalein could bind to both estrogen receptor-α (ERa) and G-protein coupled estrogen receptor 30 (GPR30), which are two critical E2-mediated pathways. Baicalein prevented the E2-induced ERa-mediated activation of nuclear transcriptional signaling by interfering with the trafficking of ERa into the nucleus and subsequent binding to estrogen response elements, thereby decreasing the mRNA levels of ERa target genes. It also inhibited E2-induced GPR30-mediated signal transduction, as well as the transcription of GPR30-regulated genes. Therefore, these results suggest that baicalein is a potential drug for reducing the risk of estrogen-dependent breast cancer.
![Creative Commons License](/images/80x15.png)
PII: 14433